Trial
NCT05814666
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Flamingo Therapeutics NV
Collaborators
—
Condition
HNSCC
Intervention
Danvatirsen
Why stopped
Interim analysis was negative
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-30